(Q42090806)

English

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

scientific article published on 8 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) (English)

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1 reference

based on heuristic

inferred from title

Andrea Rubbert-Roth

2

object named as

Andrea Rubbert-Roth

0 references

Gerd-Rüdiger Burmester

1

object named as

Gerd R Burmester

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Madura J Rangaraj

7

object named as

Madura J Rangaraj

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

8

object named as

Georgia Roane

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Charles Ludivico

9

object named as

Charles Ludivico

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

11

object named as

Lucy Rowell

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Eduardo F Mysler

13

object named as

Eduardo F Mysler

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

author name string

Andrea Rubbert-Roth

2

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Alain Cantagrel

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Stephen Hall

4

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Piotr Leszczynski

5

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Daniel Feldman

6

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Min Bao

10

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Claire Davies

12

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

language of work or name

0 references

publication date

8 June 2015

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

75

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

68-74

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Biologic agents in rheumatoid arthritis: an update for managed care professionals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

29 May 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717437

17 August 2018

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

1 reference

https://pubmed.ncbi.nlm.nih.gov/26056119

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2015-207281

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42090806&oldid=1746138829"